Clinical Scorecard: An Updated Systematic Review and Meta-Analysis of Bipolar Disorder in Individuals with Multiple Sclerosis

At a Glance

Key Highlights

• BD prevalence in people with MS (PwMS) varies widely, reported between 0% and 16.2%.
• BD in PwMS is associated with reduced medication adherence, poorer quality of life, and worsened prognosis.
• MS and BD share neuropathological features including white matter abnormalities and disrupted neural circuits regulating mood.

Guideline-Based Recommendations

Diagnosis

• Use established MS diagnostic criteria and DSM criteria for BD diagnosis.
• Consider overlapping symptoms and effects of disease-modifying therapies when diagnosing BD in PwMS.

Management

• Address both neurological and psychiatric symptoms to improve medication adherence and quality of life.
• Tailor treatment plans considering the comorbidity of MS and BD for optimal outcomes.

Monitoring & Follow-up

• Regularly monitor neuropsychiatric symptoms in PwMS to detect BD early.
• Assess medication adherence and quality of life during follow-up visits.

Risks

• Neuropsychiatric complications like BD can accelerate disability progression in MS.
• Misdiagnosis or delayed diagnosis of BD may worsen overall prognosis in PwMS.

Patient & Prescribing Data

Adults with confirmed MS diagnosis exhibiting neuropsychiatric symptoms

BD comorbidity complicates treatment adherence and requires integrated neurological and psychiatric management strategies.

Clinical Best Practices

• Implement systematic screening for BD in patients with MS to identify comorbid mood disorders early.
• Use multidisciplinary approaches involving neurology and psychiatry for comprehensive care.
• Consider the impact of disease-modifying therapies on mood symptoms when managing PwMS with BD.

References

• PRISMA Guidelines
• Newcastle–Ottawa Scale (NOS)